Intracardiac thrombus in children with dilated cardiomyopathy
Objectives: The risk of fatal pulmonary and systemic thromboembolism is high in patients with dilated cardiomyopathy with cardiac thrombus. This study was planned to reveal the efficacy of antiaggregant therapy in patients with low left ventricular systolic ejection fraction (LVEF). Study design:...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
KARE Publishing
2014-02-01
|
Series: | Türk Kardiyoloji Derneği Arşivi |
Subjects: | |
Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-81593 |
_version_ | 1828028810952441856 |
---|---|
author | Ahmet İrdem Osman Başpınar Mehmet Kervancıoğlu Metin Kılınç |
author_facet | Ahmet İrdem Osman Başpınar Mehmet Kervancıoğlu Metin Kılınç |
author_sort | Ahmet İrdem |
collection | DOAJ |
description | Objectives: The risk of fatal pulmonary and systemic thromboembolism is high in patients with dilated cardiomyopathy with cardiac thrombus. This study was planned to reveal the efficacy of antiaggregant therapy in patients with low left ventricular systolic ejection fraction (LVEF).
Study design: The present study retrospectively reviewed the files of 83 cases (42 males, 41 females) with dilated cardiomyopathy who were followed between June 2004 and December 2011.
Results: Intracardiac thrombus was detected in five (6%) cases; of these five patients, dilated cardiomyopathy was idiopathic in four and secondary to chronic renal failure in one. The cases were followed for a mean of 33.6+-35.6 months (3 days-168 months). Mean LVEF on transthoracic echocardiography was found as 35.2+-2.7% (32-38%) for the cases with intracardiac thrombus, whereas it was 34.7+-11.0% (10-55%) for the cases without intracardiac thrombus. No statistically significant difference was found between the groups (p=0.910). Cases with LVEF ≤30% were routinely receiving acetylsalicylic acid at antiaggregant dose.
Conclusion: We think that prophylactic antithrombotic/antiaggregant therapy should be started at the time of diagnosis even in patients with LVEF >30%, as thrombus development was seen in cases with LVEF >30% without any antiaggregant therapy. |
first_indexed | 2024-04-10T13:59:41Z |
format | Article |
id | doaj.art-1ece089447014ebc81e0f0ae37c89fb5 |
institution | Directory Open Access Journal |
issn | 1016-5169 |
language | English |
last_indexed | 2024-04-10T13:59:41Z |
publishDate | 2014-02-01 |
publisher | KARE Publishing |
record_format | Article |
series | Türk Kardiyoloji Derneği Arşivi |
spelling | doaj.art-1ece089447014ebc81e0f0ae37c89fb52023-02-15T16:10:19ZengKARE PublishingTürk Kardiyoloji Derneği Arşivi1016-51692014-02-0142216116710.5543/tkda.2014.81593TKDA-81593Intracardiac thrombus in children with dilated cardiomyopathyAhmet İrdem0Osman Başpınar1Mehmet Kervancıoğlu2Metin Kılınç3Department of Pediatric Cardiology, Gaziantep University Faculty of Medicine, GaziantepDepartment of Pediatric Cardiology, Gaziantep University Faculty of Medicine, GaziantepDepartment of Pediatric Cardiology, Gaziantep University Faculty of Medicine, GaziantepDepartment of Pediatric Cardiology, Gaziantep University Faculty of Medicine, GaziantepObjectives: The risk of fatal pulmonary and systemic thromboembolism is high in patients with dilated cardiomyopathy with cardiac thrombus. This study was planned to reveal the efficacy of antiaggregant therapy in patients with low left ventricular systolic ejection fraction (LVEF). Study design: The present study retrospectively reviewed the files of 83 cases (42 males, 41 females) with dilated cardiomyopathy who were followed between June 2004 and December 2011. Results: Intracardiac thrombus was detected in five (6%) cases; of these five patients, dilated cardiomyopathy was idiopathic in four and secondary to chronic renal failure in one. The cases were followed for a mean of 33.6+-35.6 months (3 days-168 months). Mean LVEF on transthoracic echocardiography was found as 35.2+-2.7% (32-38%) for the cases with intracardiac thrombus, whereas it was 34.7+-11.0% (10-55%) for the cases without intracardiac thrombus. No statistically significant difference was found between the groups (p=0.910). Cases with LVEF ≤30% were routinely receiving acetylsalicylic acid at antiaggregant dose. Conclusion: We think that prophylactic antithrombotic/antiaggregant therapy should be started at the time of diagnosis even in patients with LVEF >30%, as thrombus development was seen in cases with LVEF >30% without any antiaggregant therapy.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-81593cardiomyopathydilated/complicationschild; coronary thrombosis; thrombectomy; ventricular dysfunctionleft/complications. |
spellingShingle | Ahmet İrdem Osman Başpınar Mehmet Kervancıoğlu Metin Kılınç Intracardiac thrombus in children with dilated cardiomyopathy Türk Kardiyoloji Derneği Arşivi cardiomyopathy dilated/complications child; coronary thrombosis; thrombectomy; ventricular dysfunction left/complications. |
title | Intracardiac thrombus in children with dilated cardiomyopathy |
title_full | Intracardiac thrombus in children with dilated cardiomyopathy |
title_fullStr | Intracardiac thrombus in children with dilated cardiomyopathy |
title_full_unstemmed | Intracardiac thrombus in children with dilated cardiomyopathy |
title_short | Intracardiac thrombus in children with dilated cardiomyopathy |
title_sort | intracardiac thrombus in children with dilated cardiomyopathy |
topic | cardiomyopathy dilated/complications child; coronary thrombosis; thrombectomy; ventricular dysfunction left/complications. |
url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-81593 |
work_keys_str_mv | AT ahmetirdem intracardiacthrombusinchildrenwithdilatedcardiomyopathy AT osmanbaspınar intracardiacthrombusinchildrenwithdilatedcardiomyopathy AT mehmetkervancıoglu intracardiacthrombusinchildrenwithdilatedcardiomyopathy AT metinkılınc intracardiacthrombusinchildrenwithdilatedcardiomyopathy |